Mar 28 2011
Positron Corporation (OTCBB: POSC) is pleased to announce that its PosiRx system has met critical test standards and guidelines necessary to move on to the commercial deployment stage of its development. Following significant internal testing, Positron sought the expertise and resources of an independent 3rd party for further evaluation of its system, engaging the services the New Mexico Center for Isotopes in Medicine at the University of New Mexico (UNM) to assist in developing tests and validation protocols for the PosiRx system.
Positron installed a PosiRx Beta system at UNM in February 2011 and recently, the system successfully completed testing of key criteria required for validation. Procedures of the PosiRx system were performed with sestamibi drawn from Covidien Ultra-TechneKow® DTE (Technetium Tc 99m) generators at the University's facilities.
The PosiRx system is an automated radiopharmaceutical system that performs the complex series of steps involved in the preparation and manufacturing of unit dose SPECT pharmaceuticals such as technetium 99/sestamibi. The system was designed to meet stringent standards for compounding that include; air quality (ISO class 5), ensuring proper radiochemical purity of kits, adherence to ALARA principles for shielding the process within the equipment, product sterility, volume and activity dose accuracy through calibration, molybdenum breakthrough testing of generator elutions and basic usability.
PosiRx is the next generation of technology based on further development of the Nuclear Pharm-Assist line of pharmacy PET dispensing machines for the automation of FDG unit dose deliver. The PosiRx system provides a solution that is tailored to a wide set of users in the SPECT market that includes pharmacies, hospitals and private practices that perform diagnostic imaging. Positron will continue the development of the PosiRx system platform that will enhance its value and user base through improved software integration, and additional configurations that will handle many other radiopharmaceuticals.